医学
接触性皮炎
斑贴试验
皮肤病科
相伴的
流行病学
刺激性接触性皮炎
补丁测试
回顾性队列研究
内科学
外科
过敏
免疫学
作者
Erin M. Warshaw,Michele Buonomo,Joel G. DeKoven,James S. Taylor,D. Belsito,Howard I. Maibach,Kathryn A. Zug,Margo J. Reeder,Jonathan I. Silverberg,Amber Reck Atwater,Denis Sasseville,Joseph F. Fowler,Melanie D. Pratt,Vincent A. DeLeo,Anthony F. Fransway
出处
期刊:Dermatitis
[Ovid Technologies (Wolters Kluwer)]
日期:2021-03-08
卷期号:32 (4): 256-266
被引量:3
标识
DOI:10.1097/der.0000000000000732
摘要
Methyldibromoglutaronitrile/phenoxyethanol (MDBGN/PE) is a broad-spectrum preservative mixture used in consumer and industrial products.The aims of the study were (1) to characterize the prevalence and clinical relevance of patch test reactions to MDBGN/PE and the epidemiology of positive patients and (2) to determine the frequency of concomitant reactions of MDBGN/PE and its components.This study used a retrospective analysis of cross-sectional data compiled by the North American Contact Dermatitis Group from 1994 to 2018.Of 55,477 tested patients, 2674 (4.8%) had positive patch test reactions to MDBGN/PE (1.0%-2.5% petrolatum [pet]); most were + (63.3%) or ++ (22.3%). Clinical relevance was considered definite in 3.0% and probable in 19.3% of reactions. Common dermatitis sites included the hands (26.4%), scattered/generalized distribution (24.7%), and the face (18.3%). Patients with a positive reaction to MDBGN/PE and/or MDBGN and/or PE were significantly more likely to be male and older than 40 years and/or had hand dermatitis (P ≤ 0.0033). Positivity to MDBGN/PE 2.0% pet decreased significantly over time (from 6.0% in 1998-2000 to 2.5% in 2017-2018, P < 0.0001). Personal care products were the most common exposure source (53.2%).Over time, positivity to MDBGN/PE 2.0% pet decreased significantly from 6.0% (in 1998-2000) to 2.5% (in 2017-2018). The high proportion of weak (63.3%) reactions underscore the need for careful interpretation of patch test sites. Important demographic associations included male sex and age older than 40 years.
科研通智能强力驱动
Strongly Powered by AbleSci AI